VTRS · Viatris Inc
Market Cap
$18.77B
Shares
1.15B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.34
Open$16.93
Day$16.30–17.01
52W close$9.49–17.86
Avg vol 30d9.7M
Short int37.0M · 3.2% float · 3.0d
Short vol63%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Moderate
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+12%
above
Price vs 50-day avg
−2%
below
RSI (14)
45
neutral
MACD trend
Positive
52-week position
82%
mid-range
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+15%
trailing
YTD return
+31%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $15 — 50d above 200d
Institutional flow
Distributing
-0% holders QoQ · +115 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.22% of float · ▼ -19.0% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
1,028 holders — near 3-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
Gross margin
35%
contracting
EPS growth
−466%
Y/Y
Free cash flow
$1.9B
Buyback
$730.0M
remaining
Quant / Vol
risk profile
Volatility
32%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
2.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
U.S. GAAP net cash provided by operating activities
· full-year 2026
GAAP
Initiated
$1.7B – $2B
New product revenues
· full-year 2026
Initiated
$450M – $550M
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
U.S. GAAP net cash provided by operating activities
· 2025
$2.2B – $2.45B
Guided vs delivered
· last 1 settled
U.S. GAAP total revenues
2024 full-year
guided $14.6B – $15.1B
$14.74B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+12%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
45
Neutral
MACD trend
Positive
Bullish
52-week position
82%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $17 › 200d $15 — 50d above 200d
Institutional flow
Distributing
-0% holders QoQ · +115 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.22% of float · ▼ -19.0% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
1,028 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $16 · 82%
Range high $18
vs 200-day avg +12%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 4.4B | Twelve Months Ended June 30, 2026 | +5.7% |
|
|
|||
| Adjusted EPS non-GAAP | $1.28 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 57% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted Gross Profit non-GAAP | $4.13B | Six Months Ended June 30, 2026 | — |
| Adjusted Net Earnings non-GAAP | $1.5B | Six Months Ended June 30, 2026 | — |
|
|
|||
| EBITDA non-GAAP | $1.28B | Six Months Ended June 30, 2026 | — |
|
|
|||
| excluded anti-dilutive shares | 19.9M | the three months ended June 30, 2026 filing | — |
| Free Cash Flow non-GAAP | $677.4M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Gross debt to adjusted EBITDA non-GAAP | 2.9 | As of June 30, 2026 | — |
| quarterly cash dividend per share | $0.12 | the three months ended June 30, 2026 filing | — |
| Segment profit, Developed Markets | $937.3M | Three Months Ended June 30, 2026 filing | — |
| Segment profit, Emerging Markets | $232.3M | Three Months Ended June 30, 2026 filing | — |
| Segment profit, Greater China | $509.5M | Three Months Ended June 30, 2026 filing | — |
| Segment profit, JANZ | $76.3M | Three Months Ended June 30, 2026 filing | — |
| Segment profit, Total Reportable Segments | $1.76B | Three Months Ended June 30, 2026 filing | — |
| share repurchases | 9.4M | the three months ended June 30, 2026 filing | — |
| Adjusted earnings from operations non-GAAP | 948.9M | Q1 2026 | — |
|
|
|||
| Adjusted effective tax rate non-GAAP | 18% | Q1 2026 | — |
| Free Cash Flow (excluding transaction-related and restructuring-related costs) non-GAAP | $459M | Q1 2026 | — |
| New product revenues | $71M | Q1 2026 | — |
|
|
|||
| Adjusted earnings before income taxes non-GAAP | $3.36B | Year Ended December 31, 2025 | — |
| Adjusted income tax provision non-GAAP | $587.4M | Year Ended December 31, 2025 | — |
| Adjusted interest expense non-GAAP | $509.8M | Year Ended December 31, 2025 | — |
| Adjusted other income, net non-GAAP | -$107.1M | Year Ended December 31, 2025 | — |
| Adjusted R&D non-GAAP | $923.6M | Year Ended December 31, 2025 | — |
| Adjusted R&D as % of total revenues non-GAAP | 6% | Year Ended December 31, 2025 | — |
| Adjusted SG&A non-GAAP | $3.32B | Year Ended December 31, 2025 | — |
| Adjusted SG&A as % of total revenues non-GAAP | 23% | Year Ended December 31, 2025 | — |
| Adjusted tax expense non-GAAP | $737.5M | Year Ended December 31, 2025 | — |
| Adjusted total operating expenses non-GAAP | $4.3B | Year Ended December 31, 2025 | — |
| Free cash flow excluding the impact of transaction costs non-GAAP | $730M | Three Months Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTRS
this stock
Viatris Inc
|
$18.77B | +31.2% | -3.0% | — | 3.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +15.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.38B | +2.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTRS | +0.1% | -7.0% | +14.9% | -7.0% | +31.2% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -0.4% | -9.9% | +1.5% | -9.9% | +18.4% |
Capital returns
Latest dividend
$0.12
/ share · ex Aug 21, 2026
Paid (TTM)
$0.48
/ share · 4 payouts
Dividend yield (TTM, derived)
2.94%
Buyback program
· as of Aug 5, 2026
Authorized
$2.00B
Spent (derived)
$1.27B
Remaining
$730.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1792044
CUSIP
92556V106
13F (30d)
681 filings
624 filers
Visit website
Investor relations